Evofem Biosciences Enters into Securities Purchase Agreement and Registration Rights AgreementSAN DIEGO, California – Evofem Biosciences, Inc. (NASDAQ: EVFM) disclosed in a recent SEC filing the execution of a Securities Purchase Agreement

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Evofem Biosciences’s 8K filing here.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis.